Related Experiment Video
Updated: Dec 17, 2025

06:01
Prion Safety Laboratory Swipe Test
Published on: February 14, 2025
1.1K
Comatose within 6 weeks, but still alive after 3 years, Creutzfeldt-Jakob disease with unusual progression
Julia Kathleen Christopher1, Brian Khong2, Amin Abolfazli3
1Department of Pulmonary and Critical Care Medicine UNLV Las Vegas Nevada.
Clinical Case Reports
|June 25, 2020
Abstract:
Creutzfeldt-Jakob disease (CJD) should still be considered in a patient presenting with rapidly progressive dementia and negative CSF 14-3-3 protein and RT-QulC. Treatable causes of encephalopathy must be ruled out. Neurodegenerative diseases must also be considered.
Related Concept Videos
Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Acute Kidney Injury III: Clinical Manifestations
644
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
644
![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)
